Quick Dispatch:
Your hengrui glp 1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your hengrui glp 1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) ships.
Need Help?
Questions about hengrui glp 1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301), sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for hengrui glp 1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) in your area.
Kailera, Hengrui to advance oral obesity drug into 2 new trials
27.78
Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 | Tue, 11/04/2025
29.66
Hengrui, Kailera tout positive results for dual-acting obesity pill
20.17
Jiangsu Hengrui Competitive Landscape Analysis 2026
27.63
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
26.81
GSK forges $12bn alliance with China's Hengrui
23.35
Jiangsu Hengrui Pharmaceuticals Out-Licenses GLP-1 Portfolio // Cooley // Global Law Firm
29.28
